Fujitsu Embarks on Joint Research with National Cancer Center Japan to Create New Services for Drug Development and Clinical Trials

TOKYO, Mar 18, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced it has concluded a comprehensive collaborative research agreement with National Cancer Center Japan. The joint research will center on exploring ways that real-world data(1), including medical information from electronic records, can be leveraged to contribute to the...

Frost & Sullivan Recognizes NEC with the 2020 Global Biometrics in Security Market Growth Innovation & Leadership Excellence Frost Radar Award

TOKYO, Mar 17, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (TSE: 6701) today announced that it was presented with the 2020 Global Biometrics in Security Market Growth Innovation & Leadership Excellence Frost Radar Award by Frost & Sullivan.The award reflects NEC's pivot toward biometric solutions, which are providing...

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

TOKYO, Mar 17, 2021 - (JCN Newswire via SEAPRWire.com) - Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons...

Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu

TOKYO, Mar 16, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) led by Washington...

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

TOKYO, Mar 12, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of...

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

TOKYO, Mar 5, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer's and...